Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Constitutive activation of KIT receptor tyrosine kinase is critical in the pathogenesis of gastrointestinal stromal tumors. Imatinib mesylate, a selective tyrosine kinase inhibitor, has been shown in preclinical models and preliminary clinical studies to have activity against such tumors. METHODS: We conducted an open-label, randomized, multicenter trial to evaluate the activity of imatinib in patients with advanced gastrointestinal stromal tumor. We assessed antitumor response and the safety and tolerability of the drug. Pharmacokinetics were assessed in a subgroup of patients. RESULTS: A total of 147 patients were randomly assigned to receive 400 mg or 600 mg of imatinib daily. Overall, 79 patients (53.7 percent) had a partial response, 41 patients (27.9 percent) had stable disease, and for technical reasons, response could not be evaluated in 7 patients (4.8 percent). No patient had a complete response to the treatment. The median duration of response had not been reached after a median follow-up of 24 weeks after the onset of response. Early resistance to imatinib was noted in 20 patients (13.6 percent). Therapy was well tolerated, although mild-to-moderate edema, diarrhea, and fatigue were common. Gastrointestinal or intraabdominal hemorrhage occurred in approximately 5 percent of patients. There were no significant differences in toxic effects or response between the two doses. Imatinib was well absorbed, with pharmacokinetics similar to those reported in patients with chronic myeloid leukemia. CONCLUSIONS: Imatinib induced a sustained objective response in more than half of patients with an advanced unresectable or metastatic gastrointestinal stromal tumor. Inhibition of the KIT signal-transduction pathway is a promising treatment for advanced gastrointestinal stromal tumors, which resist conventional chemotherapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Druker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J. M., Lydon, N. B., Kantarjian, H., Capdeville, R., Ohno-Jones, S., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441401 · Cited by 5,243
Self-citationDiagnosis of gastrointestinal stromal tumors: A consensus approach
Fletcher, C. D. M., Berman, J. J., Corless, C., Gorstein, F., Lasota, J., Longley, B. J., Miettinen, M., O'Leary, T. J., Remotti, H., Rubin, B. P., et al. (2002) · Human Pathology · doi:10.1053/hupa.2002.123545 · Cited by 3,419
Self-citationClinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., & Sawyers, C. L. (2001) · Science · doi:10.1126/science.1062538 · Cited by 3,104
Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
Druker, B. J., Tamura, S., Buchdunger, E., Ohno, S., Segal, G. M., Fanning, S., Zimmermann, J., & Lydon, N. B. (1996) · Nature Medicine · doi:10.1038/nm0596-561 · Cited by 2,967
Self-citationDruker, B. J., Sawyers, C. L., Kantarjian, H., Resta, D. J., Reese, S. F., Ford, J. M., Capdeville, R., & Talpaz, M. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441402 · Cited by 2,713
Self-citationTwo Hundred Gastrointestinal Stromal Tumors: Recurrence Patterns and Prognostic Factors for Survival
DeMatteo, R. P., Lewis, J. J., Leung, D., Mudan, S. S., Woodruff, J. M., & Brennan, M. F. (2000) · Annals of Surgery · doi:10.1097/00000658-200001000-00008 · Cited by 2,554
Joensuu, H., Roberts, P. J., Sarlomo-Rikala, M., Andersson, L. C., Tervahartiala, P., Tuveson, D., Silberman, S. L., Capdeville, R., Dimitrijevic, S., Druker, B., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441404 · Cited by 2,037
Self-citationBuchdunger, E., Cioffi, C. L., Law, N., Stover, D., Ohno-Jones, S., Druker, B. J., & Lydon, N. B. (2000) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38879-2 · Cited by 1,274
Self-citationvan Oosterom, A. T., Judson, I., Verweij, J., Stroobants, S., di Paola, E. D., Dimitrijevic, S., Martens, M., Webb, A., Sciot, R., Van Glabbeke, M., et al. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06535-7 · Cited by 1,264
Self-citationHeinrich, M. C., Griffith, D. J., Druker, B. J., Wait, C. L., Ott, K. A., & Zigler, A. J. (2000) · Blood · doi:10.1182/blood.v96.3.925 · Cited by 1,071
Self-citation
Research works printed but not linked: 4
- Rubin BP, 2001, Cancer Res, 61, 8118
- Goss GA, 2000, Prog Proc Am Soc Clin Oncol, 19, 599a
- Buchdunger E, 2000, J Pharmacol Exp Ther, 295, 139
- Peng B, 2001, Prog Proc Am Soc Clin Oncol, 20, 71a
Cited by
Items 401–500 of 1,007
Targeting immune suppressing myeloid-derived suppressor cells in oncology
Kao, J., Ko, E. C., Eisenstein, S. G., Sikora, A. G., Fu, S., & Chen, S. (2010) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2010.02.004 · Cited by 151
Catenacci, D. V. T. (2015) · Molecular Oncology · doi:10.1016/j.molonc.2014.09.011 · Cited by 144
Joensuu, H., & DeMatteo, R. P. (2011) · Annual Review of Medicine · doi:10.1146/annurev-med-043010-091813 · Cited by 153
Self-citationNew treatment strategies for advanced-stage gastrointestinal stromal tumours
Klug, L. R., Khosroyani, H. M., Kent, J. D., & Heinrich, M. C. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00606-4 · Cited by 164
Self-citationAnti-angiogenic therapy: Rationale, challenges and clinical studies
Longo, R., Sarmiento, R., Fanelli, M., Capaccetti, B., Gattuso, D., & Gasparini, G. (2002) · Angiogenesis · doi:10.1023/a:1024532022166 · Cited by 170
Immunological off-target effects of imatinib
Zitvogel, L., Rusakiewicz, S., Routy, B., Ayyoub, M., & Kroemer, G. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.41 · Cited by 142
Reichardt, P., Blay, J., Gelderblom, H. A. J., Schlemmer, M., Demetri, G. D., Bui-Nguyen, B., McArthur, G. A., Yazji, S., Hsu, Y., Galetić, I., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mdr598 · Cited by 142
Self-citationImatinib Attenuates Diabetes-Associated Atherosclerosis
Lassila, M., Allen, T. J., Cao, Z., Thallas, V., Jandeleit-Dahm, K. A., Candido, R., & Cooper, M. E. (2004) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000124105.39900.db · Cited by 142
Guo, T., Agaram, N. P., Wong, G. C., Hom, G., D’Adamo, D. R., Maki, R. G., Schwartz, G. K., Veach, D. R., Clarkson, B. D., Singer, S., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0484 · Cited by 145
Self-citationSchöffski, P., Reichardt, P., Blay, J., Dumez, H., Morgan, J. A., Ray-Coquard, I., Hollaender, N., Jappe, A., & Demetri, G. D. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq076 · Cited by 144
Self-citationPDGF receptor mutations in human diseases
Guérit, E. M., Arts, F. A., Dachy, G., Boulouadnine, B., & Demoulin, J. (2021) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-020-03753-y · Cited by 150
The inhibitory anti-FGFR3 antibody, PRO-001, is cytotoxic to t(4;14) multiple myeloma cells
Trudel, S., Stewart, A. K., Rom, E., Wei, E., Li, Z. H., Kotzer, S., Chumakov, I., Singer, Y., Chang, H., Liang, S.-B., et al. (2006) · Blood · doi:10.1182/blood-2005-10-4179 · Cited by 142
Zhao, R., Song, Y., Wang, Y., Huang, Y., Li, Z., Cui, Y., Yi, M., Xia, L., Zhuang, W., Wu, X., et al. (2019) · Cell Proliferation · doi:10.1111/cpr.12571 · Cited by 161
Gastrointestinal Stromal Tumours: Consensus Statement on Diagnosis and Treatment
Blackstein, M. E., Blay, J., Corless, C. L., Driman, D. K., Riddell, R. H., Soulières, D., Swallow, C. J., & Verma, S. (2006) · Canadian Journal of Gastroenterology · doi:10.1155/2006/434761 · Cited by 156
Self-citationLasota, J. P., Stachura, J., & Miettinen, M. (2005) · Laboratory Investigation · doi:10.1038/labinvest.3700360 · Cited by 150
Wilson, J., Connock, M., Song, F., Yao, G., Fry-Smith, A., Raftery, J., & Peake, D. (2005) · Health Technology Assessment · doi:10.3310/hta9250 · Cited by 140
Ocular Toxicity of Targeted Therapies
Renouf, D. J., Velazquez-Martin, J. P., Simpson, R., Siu, L. L., & Bedard, P. L. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.41.5851 · Cited by 139
“Imatinib Imatinib mesylate, a selective inhibitor of the Bcr-Abl, c-Kit, and platelet-derived growth factor receptor tyrosine kinases, is used for the treatment of chronic myelogenous leukemia(32) and GI stromal tumors.(33) Periorbital edema is the most common ocular adverse effect of imatinib, occurring in up to 30%…”
MethodLoss of expression of SDHA predicts SDHA mutations in gastrointestinal stromal tumors
Wagner, A. J., Remillard, S. P., Zhang, Y., Doyle, L. A., George, S., & Hornick, J. L. (2012) · Modern Pathology · doi:10.1038/modpathol.2012.153 · Cited by 144
FGFR3-TACC3 fusion in solid tumors: mini review
Costa, R. L. B., Carneiro, B. A., Taxter, T., Tavora, F. A., Kalyan, A., Pai, S. G., Chae, Y. K., & Giles, F. J. (2016) · Oncotarget · doi:10.18632/oncotarget.10482 · Cited by 142
Gibbons, J., Egorin, M. J., Ramanathan, R. K., Fu, P., Mulkerin, D. L., Shibata, S., Takimoto, C. H. M., Mani, S., LoRusso, P. M., Grem, J. L., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.3819 · Cited by 146
Oostendorp, R. L., Buckle, T., Beijnen, J. H., van Tellingen, O., & Schellens, J. H. M. (2008) · Investigational New Drugs · doi:10.1007/s10637-008-9138-z · Cited by 137
Imaging of gastrointestinal stromal tumour (GIST)
Lau, S. H. Y., Tam, K., Kam, C. K., Lui, C. Y., Siu, C. W., Lam, H. S., & Mak, K. L. (2004) · Clinical Radiology · doi:10.1016/j.crad.2003.10.018 · Cited by 136
Desai, J., Shankar, S., Heinrich, M. C., Fletcher, J. A., Fletcher, C. D. �., Manola, J., Morgan, J. A., Corless, C. L., George, S., Tuncali, K., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0858 · Cited by 135
Self-citationManagement of gastrointestinal stromal tumors: from diagnosis to treatment
Egger, J. (2004) · Swiss Medical Weekly · doi:10.4414/smw.2004.10530 · Cited by 135
Kamel, H. F. M., & Al-Amodi, H. S. A. B. (2017) · Genomics Proteomics & Bioinformatics · doi:10.1016/j.gpb.2016.11.005 · Cited by 156
Gastrointestinal stromal tumors and leiomyosarcomas
Katz, S. C., & DeMatteo, R. P. (2008) · Journal of Surgical Oncology · doi:10.1002/jso.20970 · Cited by 141
Novel Therapeutic Targets in Non-small Cell Lung Cancer
Jankú, F., Garrido‐Laguna, I., Petruzelka, L. B., Stewart, D. J., & Kurzrock, R. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31822944b3 · Cited by 139
Targeting aerobic glycolysis: 3-bromopyruvate as a promising anticancer drug
Cardaci, S., Desideri, E., & Ciriolo, M. R. (2012) · Journal of Bioenergetics and Biomembranes · doi:10.1007/s10863-012-9422-7 · Cited by 140
Towards novel paradigms for cancer therapy
Pavet, V., Portal, M. M., Moulin, J.-F., Herbrecht, R., & Gronemeyer, H. (2010) · Oncogene · doi:10.1038/onc.2010.460 · Cited by 143
Roberts, K. G., Smith, A. M., McDougall, F., Carpenter, H., Horan, M., Neviani, P., Powell, J. A., Thomas, D., Guthridge, M. A., Perrotti, D., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-2544 · Cited by 133
Imatinib Targeting of KIT-Mutant Oncoprotein in Melanoma
Jiang, X., Zhou, J., Yuen, N. K., Corless, C. L., Heinrich, M. C., Fletcher, J. A., Demetri, G. D., Widlund, H. R., Fisher, D. E., & Hodi, F. S. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1144 · Cited by 140
Self-citationEffects of systemic chemotherapy on the liver
Ramadori, G., & Cameron, S. (2010) · Annals of Hepatology · doi:10.1016/s1665-2681(19)31651-5 · Cited by 132
Demetri, G. D., Heinrich, M. C., Fletcher, J. A., Fletcher, C. D. �., den Abbeele, A. D. V., Corless, C. L., Antonescu, C. R., George, S., Morgan, J. A., Chen, M. H., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0482 · Cited by 133
Self-citationHägerkvist, R., Sandler, S., Mokhtari, D., & Welsh, N. (2007) · The FASEB Journal · doi:10.1096/fj.06-6910com · Cited by 132
Targeting Cancer with Small-Molecular-Weight Kinase Inhibitors
Fabbro, D., Cowan-Jacob, S. W., Möbitz, H., & Martiny-Baron, G. (2012) · Methods in Molecular Biology · doi:10.1007/978-1-61779-337-0_1 · Cited by 127
Blesius, A., Cassier, P. A., Bertucci, F., Fayette, J., Ray-Coquard, I. L., Bui, B., Adenis, A., Rios, M., Cupissol, D., Pérol, D., et al. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-72 · Cited by 129
Imatinib targets other than bcr/abl and their clinical relevance in myeloid disorders
Pardanani, A., & Tefferi, A. (2004) · Blood · doi:10.1182/blood-2004-01-0246 · Cited by 129
Outcome of Metastatic GIST in the Era before Tyrosine Kinase Inhibitors
Gold, J. S., van der Zwan, S. M., Gönen, M., Maki, R. G., Singer, S., Brennan, M. F., Antonescu, C. R., & DeMatteo, R. P. (2006) · Annals of Surgical Oncology · doi:10.1245/s10434-006-9177-7 · Cited by 132
Self-citationTomizawa, Y., Iijima, H., Sunaga, N., Sato, K., Takise, A., Otani, Y., Tanaka, S., Suga, T., Saito, R., Ishizuka, T., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0441 · Cited by 130
Gastric GI stromal tumors (GISTs): The role of surgery in the era of targeted therapy
Heinrich, M. C., & Corless, C. L. (2005) · Journal of Surgical Oncology · doi:10.1002/jso.20230 · Cited by 129
Self-citationTrent, J. C., Beach, J. L., Burgess, M. A., Papadopolous, N., Chen, L. L., Benjamin, R. S., & PATEL, S. R. (2003) · Cancer · doi:10.1002/cncr.11875 · Cited by 129
Martinho, O., Longatto‐Filho, A., Lambros, M. B., Martins, A. M., Pinheiro, C. M., da Silva, A. S. L., Pardal, F., de Amorim, J. A., Mackay, A. G., Milanezi, F., et al. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605225 · Cited by 146
Cesne, A. L., Blay, J., Bui, B., Bouché, O., Adenis, A., Dômont, J., Cioffi, A., Ray-Coquard, I. L., Lassau, N., Bonvalot, S., et al. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2010.02.014 · Cited by 128
Wu, C., Tzen, C., Wang, S., & Yeh, C. (2019) · Cancers · doi:10.3390/cancers11050679 · Cited by 134
Kurokawa, Y., Honma, Y., Sawaki, A., Naito, Y., Iwagami, S., Komatsu, Y., Takahashi, T., Nishida, T., & Doi, T. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.05.518 · Cited by 127
Sneed, T. B., Kantarjian, H. M., Talpaz, M., O'Brien, S., Rios, M. B., Bekele, B. N., Zhou, X., Resta, D., Wierda, W., Faderl, S., et al. (2004) · Cancer · doi:10.1002/cncr.11863 · Cited by 127
Distinct Gene Expression–Defined Classes of Gastrointestinal Stromal Tumor
Yamaguchi, U., Nakayama, R. T., Honda, K., Ichikawa, H., Hasegawa, T., Shitashige, M., Ono, M., Shoji, A., Sakuma, T., Kuwabara, H., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.2331 · Cited by 126
Relationship of imatinib-free plasma levels and target genotype with efficacy and tolerability
Widmer, N., Decosterd, L. A., Leyvraz, S., Duchosal, M. A., Rosselet, A., Dêbiec‐Rychter, M., Csajka, C., Biollaz, J., & Buclin, T. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604355 · Cited by 138
Practical management of tyrosine kinase inhibitor-associated side effects in GIST
Joensuu, H., Trent, J. C., & Reichardt, P. (2010) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2010.04.008 · Cited by 127
Self-citationMénétrier disease and gastrointestinal stromal tumors: hyperproliferative disorders of the stomach
Coffey, R. J., Washington, M. K., Corless, C. L., & Heinrich, M. C. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30491 · Cited by 143
Self-citationSurgical treatment of gastrointestinal stromal tumors in the imatinib (STI-571) era
Wu, P., Langerman, A. J., Ryan, C. W., Hart, J. A. L., Swiger, S., & Posner, M. C. (2003) · Surgery · doi:10.1016/s0039-6060(03)00314-3 · Cited by 126
Monitoring cancer treatment with PET/CT: does it make a difference?
Weber, W., & Figlin, R. A. (2007) · PubMed · Cited by 151
Duensing, A. U., Joseph, N. E., Medeiros, F., Smith, F., Hornick, J. L., Heinrich, M. C., Corless, C. L., Demetri, G. D., Fletcher, C. D. �., & Fletcher, J. A. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0559 · Cited by 125
Self-citationAgaram, N. P., Besmer, P., Wong, G. C., Guo, T., Socci, N. D., Maki, R. G., DeSantis, D., Brennan, M. F., Singer, S., DeMatteo, R. P., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1508 · Cited by 128
Self-citationDimitrakopoulou‐Strauss, A., Hohenberger, P., Haberkorn, U., Mäcke, H. R., Eisenhut, M., & Strauss, L. G. (2007) · Journal of Nuclear Medicine · doi:10.2967/jnumed.106.038091 · Cited by 124
The GIST paradigm: lessons for other kinase‐driven cancers
Antonescu, C. R. (2010) · The Journal of Pathology · doi:10.1002/path.2798 · Cited by 133
Packer, L. M., Rana, S., Hayward, R., O'Hare, T., Eide, C. A., Rebocho, A., Heidorn, S., Zabriskie, M. S., Niculescu-Duvaz, I., Druker, B. J., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.11.004 · Cited by 124
Self-citationGastrointestinal Stromal Tumors: Biology and Treatment
Duffaud, F., & Blay, J. (2003) · Oncology · doi:10.1159/000074470 · Cited by 123
Imatinib mesylate for the treatment of gastrointestinal stromal tumours: best monitored with FDG PET
Jager, P. L., Gietema, J. A., & van der Graaf, W. T. A. (2004) · Nuclear Medicine Communications · doi:10.1097/00006231-200405000-00002 · Cited by 123
Ocular Side-Effects Associated with Imatinib Mesylate (Gleevec ® )
Fraunfelder, F. W., Solomon, J., Druker, B. J., Esmaeli, B., & Kuyl, J. (2003) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/108076803322279426 · Cited by 123
Self-citationHeinrich, M. C., Rankin, C. J., Blanke, C. D., Demetri, G. D., Borden, E. C., Ryan, C. W., von Mehren, M., Blackstein, M. E., Priebat, D. A., Tap, W. D., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2016.6728 · Cited by 140
Self-citationZhang, W., Xu, W., Lan, Y., He, X., Liu, K., & Liang, Y. (2019) · International Journal of Nanomedicine · doi:10.2147/ijn.s203113 · Cited by 123
Sunaga, N., Oriuchi, N., Kaira, K., Yanagitani, N., Tomizawa, Y., Hisada, T., Ishizuka, T., Endo, K., & Mori, M. (2007) · Lung Cancer · doi:10.1016/j.lungcan.2007.08.012 · Cited by 126
Hahn, S. M., Fraker, D. L., Mick, R., Metz, J. M., Busch, T. M., Smith, D., Zhu, T. C., Rodríguez, C., Dimofte, A., Spitz, F. J., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1625 · Cited by 132
Matei, D. E., Chang, D. D., & Jeng, M. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-0754-03 · Cited by 136
Bench to Bedside: Mapping the Moral Terrain of Clinical Research
Joffe, S., & Miller, F. G. (2008) · Hastings Center Report · doi:10.1353/hcr.2008.0019 · Cited by 122
“” These articles define the logical structure of the Declaration: (1) the researcher is first and foremost a physician; (2) clinical research is a special case of medical care; (3) therefore, physicians’ duties to their pa-”
BackgroundContrast-Enhanced Dual-Energy CT of Gastrointestinal Stromal Tumors
Apfaltrer, P., Meyer, M., Meier, C., Henzler, T., Barraza, J. M., Dinter, D. J., Hohenberger, P., Schoepf, U. J., Schoenberg, S. O., & Fink, C. (2011) · Investigative Radiology · doi:10.1097/rli.0b013e31823003d2 · Cited by 121
KIT as a Therapeutic Target in Melanoma
Garrido, M. C., & Bastian, B. C. (2009) · Journal of Investigative Dermatology · doi:10.1038/jid.2009.334 · Cited by 131
MK1775, a Selective Wee1 Inhibitor, Shows Single-Agent Antitumor Activity against Sarcoma Cells
Kreahling, J. M., Gemmer, J. Y., Reed, D., Letson, D., Bui, M., & Altiok, S. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0529 · Cited by 120
Phase II Study of Imatinib Mesylate in Chemotherapy Refractory Germ Cell Tumors Expressing KIT
Einhorn, L. H., Brames, M. J., Heinrich, M. C., Corless, C. L., & Madani, A. (2006) · American Journal of Clinical Oncology · doi:10.1097/01.coc.0000195086.47548.ef · Cited by 122
Self-citationFletcher, J. A., & Rubin, B. P. (2007) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2006.12.010 · Cited by 121
Self-citationSTK33 Kinase Activity Is Nonessential in KRAS-Dependent Cancer Cells
Babij, C., Zhang, Y., Kurzeja, R. J., Munzli, A., Shehabeldin, A., Fernando, M., Quon, K., Kassner, P. D., Ruefli-Brasse, A. A., Watson, V. J., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0778 · Cited by 122
Blay, J., Shen, L., Kang, Y., Rutkowski, P. L., Qin, S., Nosov, D., Wan, D., Trent, J. C., Srimuninnimit, V., Pápai, Z., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70105-1 · Cited by 120
Self-citationCroom, K. F., & Perry, C. M. (2003) · Drugs · doi:10.2165/00003495-200363050-00005 · Cited by 120
Induced-fit docking studies of the active and inactive states of protein tyrosine kinases
Zhong, H. A., Tran, L. M., & Stang, J. L. (2009) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2009.08.012 · Cited by 122
Tsurutani, J., West, K. A., Sayyah, J., Gills, J. J., & Dennis, P. A. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0058 · Cited by 129
Tarn, C., Merkel, E., Canutescu, A. A., Shen, W., Skorobogatko, Y. V., Heslin, M. J., Eisenberg, B. L., Birbe, R., Patchefsky, A. S., Dunbrack, R. L., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2515 · Cited by 120
Self-citationGenomic Medicine Frontier in Human Solid Tumors: Prospects and Challenges
Dienstmann, R., Rodon, J., Barretina, J., & Tabernero, J. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.2268 · Cited by 117
An audit of surgical management of gastrointestinal stromal tumours (GIST)
Bucher, P., Egger, J. ‐., Gervaz, P., Ris, F., Weintraub, D., Villiger, P., Bühler, L. H., & Morel, P. (2006) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2005.11.021 · Cited by 119
Surgical management of gastrointestinal stromal tumours
Gervaz, P., Huber, O., & Morel, P. (2009) · British journal of surgery · doi:10.1002/bjs.6601 · Cited by 128
Mutations in gastrointestinal stromal tumors – a population‐based study from Northern Norway
Steigen, S. E., Eide, T. J., Wasąg, B., Lasota, J. P., & Miettinen, M. (2007) · Apmis · doi:10.1111/j.1600-0463.2007.apm_587.x · Cited by 118
Gastrointestinal stromal tumor.
Zhao, X., & Yue, C. (2012) · PubMed · doi:10.3978/j.issn.2078-6891.2012.031 · Cited by 168
Kataoka, Y., Mukohara, T., Tomioka, H., Funakoshi, Y., Kiyota, N., Fujiwara, Y., Yashiro, M., Hirakawa, K., Hirai, M., & Minami, H. (2011) · Investigational New Drugs · doi:10.1007/s10637-011-9699-0 · Cited by 124
Hawkins, D. S., Conrad, E. U., Butrynski, J. E., Schuetze, S. M., & Eary, J. F. (2009) · Cancer · doi:10.1002/cncr.24421 · Cited by 121
Dermatofibrosarcoma Protuberans: Recent Clinical Progress
McArthur, G. A. (2007) · Annals of Surgical Oncology · doi:10.1245/s10434-007-9480-y · Cited by 118
van Dongen, M., Savage, N. D. L., Jordanova, E. S., Briaire‐de Bruijn, I. H., Walburg, K. V., Ottenhoff, T. H. M., Hogendoorn, P. C. W., van der Burg, S. H., Gelderblom, H., & van Hall, T. (2010) · International Journal of Cancer · doi:10.1002/ijc.25113 · Cited by 118
Andriamanana, I., Gana, I., Duretz, B., & Lesne-Hulin, A. (2013) · Journal of Chromatography B · doi:10.1016/j.jchromb.2013.01.037 · Cited by 127
Gan, H. K., Šeruga, B., & Knox, J. J. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780902980171 · Cited by 129
Development of synthetic lethality in cancer: molecular and cellular classification
Li, S., Topatana, W., Juengpanich, S., Cao, J., Hu, J., Zhang, B., Ma, D., Cai, X., & Chen, M. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00358-6 · Cited by 115
Sunitinib malate for the treatment of solid tumours: a review of current clinical data
Motzer, R. J., Hoosen, S., Bello, C. L., & Christensen, J. G. (2006) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.15.5.553 · Cited by 119
Park, S. H., Ryu, M., Ryoo, B., Im, S., Kwon, H.-C., Lee, S. S., Park, S. R., Kang, B. Y., & Kang, Y. (2012) · Investigational New Drugs · doi:10.1007/s10637-012-9795-9 · Cited by 117
Demetri, G. D. (2002) · European Journal of Cancer · doi:10.1016/s0959-8049(02)80603-7 · Cited by 117
Self-citationTYROSINE KINASE INHIBITORS AND THE DAWN OF MOLECULAR CANCER THERAPEUTICS
Tibes, R., Trent, J. C., & Kurzrock, R. (2004) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.45.120403.100124 · Cited by 133
Carney, J. A. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-1156 · Cited by 116
Ma, W. W., Jacene, H., Song, D., Vilardell, F., Messersmith, W. A., Laheru, D., Wahl, R., Endres, C., Jimeno, A., Pomper, M. G., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.8383 · Cited by 116
Growth Factor Receptors in Breast Cancer: Potential for Therapeutic Intervention
Nahta, R., Hortobágyi, G. N., & Esteva, F. J. (2003) · The Oncologist · doi:10.1634/theoncologist.8-1-5 · Cited by 135
Update on the Biology and Therapy of Gastrointestinal Stromal Tumors
D’Amato, G. Z., Steinert, D. M., McAuliffe, J. C., & Trent, J. C. (2005) · Cancer Control · doi:10.1177/107327480501200106 · Cited by 130
Mahmood, S., Agresta, S. V., Vigil, C. E., Zhao, X., Han, G., D’Amato, G. Z., Calitri, C. E., Dean, M. L., Garrett, C. R., Schell, M. J., et al. (2010) · International Journal of Cancer · doi:10.1002/ijc.25843 · Cited by 115
Molecular Mechanism and Prevention Strategy of Chemotherapy- and Radiotherapy-Induced Ovarian Damage
Kim, S., Kim, S. W., Han, S.-J., Lee, S., Park, H., Song, J. Y., & Kim, T. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22147484 · Cited by 131
Kang, Y., George, S., Jones, R. L., Rutkowski, P. L., Shen, L., Mir, O., PATEL, S. R., Zhou, Y., von Mehren, M., Hohenberger, P., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.00217 · Cited by 119
Self-citation
Metadata
- Authors
- Demetri, G. D., von Mehren, M., Blanke, C. D., Van den Abbeele, A. D., Eisenberg, B., Roberts, P. J., Heinrich, M. C., Tuveson, D. A., Singer, S., Janicek, M., Fletcher, J. A., Silverman, S. G., Silberman, S. L., Capdeville, R., Kiese, B., Peng, B., Dimitrijevic, S., Druker, B. J., Corless, C., Fletcher, C. D. M., & Joensuu, H.
- Affiliations
- Harvard University (US)
- Oregon Health & Science University (US)
- Fox Chase Cancer Center (US)
- Novartis (Switzerland) (CH)
- University of Helsinki (FI)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2002-08-15
- Volume
- 347
- Issue
- 7
- Pages
- 472-480
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2015015957
- Cited by
- 4,389
- References
- 21
- Citations by year
- 2026: 85 · 2025: 91 · 2024: 107 · 2023: 115 · 2022: 117 · 2021: 128 · 2020: 136 · 2019: 119 · 2018: 131 · 2017: 136 · 2016: 160 · 2015: 182 · 2014: 192 · 2013: 210 · 2012: 255
- FWCI
- 167.44
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- CRC Press eBooks (publishedVersion)
- PubMed (publishedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- Funders
- U.S. Department of Veterans Affairs
- Northwest Health Foundation
- Helsingin Yliopisto
- Topics
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal Tumor Research and Treatment
- Life Sciences › Immunology and Microbiology › Immunology › Mast cells and histamine
- Health Sciences › Medicine › Oncology › Gastric Cancer Management and Outcomes
- Keywords
- imatinib mesylate, gastrointestinal stromal tumor, KIT receptor tyrosine kinase, tyrosine kinase inhibitors, antitumor immunity, drug resistance, pharmacokinetics, adverse effects, metastatic cancer, dose comparison
- MeSH terms
- Imatinib Mesylate, Adolescent, Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Benzamides, Female, Gastrointestinal Neoplasms, Humans, Male, Middle Aged, Piperazines, Protein-Tyrosine Kinases, Pyrimidines, Remission Induction, Signal Transduction, Survival Analysis, Stromal Cells, Proto-Oncogene Proteins c-kit
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.